Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATX NYSE:FTT CVE:HEM CVE:NSCI CVE:PAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.10-9.1%C$0.10C$0.06▼C$0.43C$18.11M0.852719344,158 shs193,004 shsNSCINanalysis ScientificC$0.19C$0.21C$0.18▼C$0.40C$21.24M-0.96866887,474 shs13,150 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%HEMHemostemix+4.76%0.00%+4.76%-18.52%+69.23%NSCINanalysis Scientific-7.50%-13.95%-2.63%-21.28%-49.32%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.10-9.1%C$0.10C$0.06▼C$0.43C$18.11M0.852719344,158 shs193,004 shsNSCINanalysis ScientificC$0.19C$0.21C$0.18▼C$0.40C$21.24M-0.96866887,474 shs13,150 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%HEMHemostemix+4.76%0.00%+4.76%-18.52%+69.23%NSCINanalysis Scientific-7.50%-13.95%-2.63%-21.28%-49.32%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXCosta 0.00N/AN/AN/AFTTFederated Enhanced Treasury Income Fund 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/ANSCINanalysis Scientific 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXCostaN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/ANSCINanalysis ScientificC$43.03M0.49C$0.02 per share8.93C$0.21 per share0.88PASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXCostaN/AN/A0.00N/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/A0.00N/AN/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/ANSCINanalysis Scientific-C$12.93M-C$0.11N/A∞N/A-32.75%-38.02%-7.55%N/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXCostaN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXCostaN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AHEMHemostemix-55.070.040.48NSCINanalysis Scientific71.721.421.11PASPascal Biosciences882.790.030.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemixN/ANSCINanalysis Scientific0.03%PASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemix10.43%NSCINanalysis Scientific3.95%PASPascal Biosciences15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXCostaN/AN/AN/ANot OptionableFTTFederated Enhanced Treasury Income FundN/AN/AN/ANot OptionableHEMHemostemixN/A181.05 millionN/ANot OptionableNSCINanalysis Scientific249114.82 millionN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableHEM, NSCI, ATX, FTT, and PAS HeadlinesRecent News About These CompaniesPete Davidson Defends Pedro Pascal From Online Trolls Who Say He’s In Everything: “You’ve Got To Give Someone Time To Adjust To That New Level Of Fame”September 27, 2025 | deadline.comDPete Davidson defends Pedro Pascal against online criticsSeptember 27, 2025 | msn.comPete Davidson Says Social Media “Can’t Wait” to Turn On Celebs Like Pedro PascalSeptember 27, 2025 | vanityfair.comVPete Davidson defends 'The Last of Us' star Pedro PascalSeptember 26, 2025 | msn.comPete Davidson Predicts Fans Will “Turn” on Walton Goggins Similar to Pedro Pascal Oversaturation BacklashSeptember 26, 2025 | hollywoodreporter.comHPedro Pascal Gets Support From Unexpected Actor Amid Recent CriticismSeptember 26, 2025 | msn.comPete Davidson Calls Out Social Media for Turning on Pedro Pascal So Fast: He ‘Blows Up,’ Becomes ‘Daddy’ and Then Everyone’s Like ‘Go the F— Away’September 25, 2025 | variety.comVPete Davidson Defends Pedro Pascal From Online Trolls Who Say He’s In Everything: “You’ve Got To Give Someone Time To Adjust To That New Level Fame”September 25, 2025 | msn.comPete Davidson Defends Pedro Pascal from Online Critics, Says People 'Can't Wait' to Tear Down CelebritiesSeptember 25, 2025 | msn.comPedro Pascal and Baby Yoda Return to “Star Wars” in Action-Packed “The Mandalorian and Grogu” TrailerSeptember 24, 2025 | yahoo.comPedro Pascal, Baby Yoda return in 'Star Wars: The Mandalorian and Grogu' trailerSeptember 22, 2025 | abcnews.go.comPedro Pascal starrer 'The Mandalorian and Grogu' from 'Star Wars' universe trailer outSeptember 22, 2025 | news.webindia123.comNPedro Pascal Defends Jimmy Kimmel Amid ABC Suspension: "Standing With You"September 21, 2025 | msn.comPedro Pascal's Sister Lux Pascal Praises The Fantastic Four Star For Supporting Her Trans Identity Early OnSeptember 19, 2025 | msn.comPedro Pascal’s Reaction to Joseph Quinn’s Jump Scare Is Pure ComedySeptember 19, 2025 | yahoo.comBella Ramsey Wants Spider-Man Role and Heist Film with Pedro PascalSeptember 16, 2025 | themovieblog.comTPascal AI Raises $3.1 Million to Accelerate Autonomous Investment Research WorkflowsSeptember 15, 2025 | finance.yahoo.comThe Original Calculator? Blaise Pascal’s Mechanical Marvel Could Fetch Millions at AuctionSeptember 13, 2025 | news.artnet.comNActor Pedro Pascal takes Pedro Piscal brand brandy to court in ChileSeptember 12, 2025 | msn.comPedro Pascal's future as The Mandalorian's Din Djarin just got a big updateSeptember 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Downgraded But Not Done: 3 Stocks Ready for a Market ComebackBy Thomas Hughes | September 24, 20255 Stocks Congress Quietly Bought in Q3—Should You Follow?By Thomas Hughes | October 10, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 2025Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?By Gabriel Osorio-Mazilli | September 29, 2025HEM, NSCI, ATX, FTT, and PAS Company DescriptionsCosta NASDAQ:ATXCosta Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.Federated Enhanced Treasury Income Fund NYSE:FTTFederated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.Hemostemix CVE:HEMC$0.10 -0.01 (-9.09%) As of 01:36 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Nanalysis Scientific CVE:NSCIC$0.18 0.00 (0.00%) As of 01:22 PM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Intel's Turnaround Hits Hyperspeed With A New 52-Week High Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Energy Crunch Ahead: 3 Natural Gas Stocks Set to Gain Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
